Alcami, a contract development and manufacturing organisation (CDMO), announced on Tuesday that it has completed Phase II of its cGMP biostorage facility situated in Amherst, New Hampshire.
The company's 104,000 square feet area is now completely operational and supports various cGMP storage requirements. The whole site covers a total area of 160,000 square feet.
The company is planning to complete phase III in the first quarter of 2023 and will add an additional 56,000 square feet of new capacity.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval